851220-85-4

851220-85-4 structure

Name: 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one,hydrate
Chemical Name: 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one,hydrate
CAS Number: 851220-85-4
Molecular Formula: C₂₃H₂₉Cl₂N₃O₃
Molecular Weight: 466.40100
Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
Create Date: 2016-09-24 02:54:35
Modify Date: 2024-01-22 13:25:09
Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19[1][2][3][4].

Name	7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one,hydrate
Synonyms	7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone hydrate 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril monohydrate Aripiprazole monohydrate aripiprazole hydrate Aripiprazole hydrate 7-(4-[4-(2,3-dichloropheny)-1-piperazinyl]-butoxy)-3,4-dihydrocarbostyril monohydrate 7-(4-[4-(2,3-dichloropheny)-1-piperazinyl]-butoxy)-3,4-dihydro-2(1H)-quinolone monohydrate

Description	Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19[1][2][3][4].
Related Catalog	Research Areas >> Infection Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Research Areas >> Inflammation/Immunology Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor
Target	5-HT1A Receptor 5-HT2A Receptor 5-HT2B Receptor 5-HT2C Receptor D2 Receptor D3 Receptor D4 Receptor
In Vitro	Aripiprazole monohydrate potently activates D2 receptor-mediated inhibition of cAMP accumulation[1]. Aripiprazole monohydrate shows a greater anti-inflammatory effect on TNF-α, IL-13, IL-17α and fractalkine[3].
In Vivo	Aripiprazole monohydrate (0-3 mg/kg, IP, daily) shows some anxiolytic properties[4]. Animal Model: WAG/Rij rats (N = 6 per dose, 6 months, administration of a mixture of tiletamine/zolazepam)[4] Dosage: 0, 0.3, 1, 3 mg/kg Administration: IP, 1 mL/kg, every day at 5 p.m. until the end of the experiments Result: Showed some anxiolytic properties with the 1 mg/kg dose being the most active.
References	[1]. Burris KD, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9. [2]. Davies MA, et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 Winter;10(4):317-36. [3]. Crespo-Facorro B, et al. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol. 2021 Mar 2;12:646701. [4]. Russo E, et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013 Jan;64:371-9.

Molecular Formula	C₂₃H₂₉Cl₂N₃O₃
Molecular Weight	466.40100
Exact Mass	465.15900
PSA	57.53000
LogP	4.88300

129722-12-9

~96%

851220-85-4

Literature: BRISTOL-MYERS SQUIBB COMPANY Patent: WO2005/41970 A1, 2005 ; Location in patent: Page/Page column 7; 14 ;

884596-21-8

851220-85-4

Literature: SYNTHON B.V. Patent: WO2006/53780 A1, 2006 ; Location in patent: Page/Page column 23 ;

56-41-7	108-65-6
56-35-9	64-17-5
67-56-1	108-88-3
141-78-6	1310-73-2
13463-67-7	1333-86-4